A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

Alex Sparreboom, Judith van Asperen, Ulrich Mayer et al. · Proceedings of the National Academy of Sciences · 1997 · 880 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Phase I and Pharmacokinetic Study of Oral Paclitaxel

Mirte M. Malingré, Jetske M. Meerum Terwogt, Jos H. Beijnen et al. · Journal of Clinical Oncology · 2000 · 99 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel

Jin‐Oh Kwak, Sung Hee Lee, Gwan Sun Lee et al. · European Journal of Pharmacology · 2009 · 82 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

Yoon‐Koo Kang, Min‐Hee Ryu, Se Hoon Park et al. · Annals of Oncology · 2018 · 62 citations · Full text

Medicine, Oncology, Pharmacotherapy +11